History of macrolide use in pediatrics.

Erythromycin, the prototypical macrolide, has been widely used since the 1950s in the management of pediatric infections. Erythromycin is the drug of choice for infants and children with Legionnaire's disease, pertussis, diphtheria, lower respiratory tract infections caused by Mycoplasma pneumoniae, Chlamydia pneumoniae and Chlamydia trachomatis and enteritis caused by Campylobacter jejuni. It is also indicated for treatment of syphilis; for streptococcal, staphylococcal and pneumococcal infections; genital infections caused by Ureaplasma urealyticum; and for the prevention of rheumatic fever and endocarditis in patients who are allergic to beta-lactam antibiotics. The new macrolides azithromycin and clarithromycin are also active against Borrelia burgdorferi, Helicobacter pylori, Mycobacterium avium-intracellulare complex, Cryptosporidium spp. and Toxoplasma gondii. Erythromycin is associated with a low risk of serious side effects, although gastric distress occurs in a significant proportion of patients. Drug interactions with theophylline, carbamazepine, warfarin, cyclosporine, terfenadine and digoxin limit erythromycin use. The newer macrolides azithromycin and clarithromycin are more stable, better absorbed and better tolerated than erythromycin. Azithromycin is more active than erythromycin against Haemophilus influenzae. Excellent tissue and intracellular penetration may contribute to their clinical efficacy. In children both azithromycin and clarithromycin are indicated for acute otitis media caused by Streptococcus pneumoniae, H. influenzae and Moraxella catarrhalis and for pharyngitis/tonsillitis caused by Streptococcus pyogenes. (As of December, 1996, azithromycin for oral suspension was approved for community-acquired pneumonia in children caused by C. pneumoniae, H. influenzae, M. pneumoniae and S. pneumoniae.) Claritromycin is also indicated for acute maxillary sinusitis, uncomplicated skin and skin structure infections, pneumonia and disseminated mycobacterial infections. Azithromycin and clarithromycin are associated with a lower incidence of gastrointestinal side effects, a low rate of drug discontinuation caused by side effects and a low potential for interaction with other drugs.

[1]  G. Mccracken.  Microbiologic activity of the newer macrolide antibiotics. , 1997, The Pediatric infectious disease journal.

[2]  M. Nahata.  Drug interactions with azithromycin and the macrolides: an overview. , 1996, The Journal of antimicrobial chemotherapy.

[3]  M. Nahata.  Pharmacokinetics of azithromycin in pediatric patients: comparison with other agents used for treating otitis media and streptococcal pharyngitis , 1995 .

[4]  D. Fish,et al.  Penetration of clarithromycin into lung tissues from patients undergoing lung resection , 1994, Antimicrobial Agents and Chemotherapy.

[5]  L. Miller,et al.  Ototoxicity with azithromycin , 1994, The Lancet.

[6]  N. Siepman,et al.  Overview of the safety profile of clarithromycin suspension in pediatric patients , 1993, The Pediatric infectious disease journal.

[7]  R. Fass.  Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance , 1993, Antimicrobial Agents and Chemotherapy.

[8]  R. Wallace,,et al.  Drug intolerance to high-dose clarithromycin among elderly patients. , 1993, Diagnostic microbiology and infectious disease.

[9]  E. Mini,et al.  Pharmacokinetic Drug Interactions of Macrolides , 1992, Clinical pharmacokinetics.

[10]  P. Fairclough,et al.  Erythromycin and the gut. , 1992, Gut.

[11]  M. Nahata,et al.  The New Macrolide Antibiotics: Azithromycin, Clarithromycin, Dirithromycin, and Roxithromycin , 1992, The Annals of pharmacotherapy.

[12]  G. Sides,et al.  New directions for macrolide antibiotics: structural modifications and in vitro activity , 1989, Antimicrobial Agents and Chemotherapy.

[13]  R. Isaacson,et al.  In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection , 1989, Antimicrobial Agents and Chemotherapy.

[14]  R. Anderson,et al.  An in-vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent. , 1988, The Journal of antimicrobial chemotherapy.

[15]  B. Rosner,et al.  Effect on birth weight of erythromycin treatment of pregnant women , 1987, Obstetrics and gynecology.

[16]  J A Washington,et al.  Erythromycin: a microbial and clinical perspective after 30 years of clinical use (2). , 1985, Mayo Clinic proceedings.

[17]  John A. Washington,et al.  Erythromycin: A Microbial and Clinical Perspective After 30 Years of Clinical Use (First of Two Parts)* , 1985 .

[18]  G. Reisz,et al.  The effect of erythromycin on theophylline pharmacokinetics in chronic bronchitis. , 1983, The American review of respiratory disease.

[19]  Eck Mr,et al.  Letter: Effect of benzodiazepines in neonates. , 1975 .

[20]  P. Braun.  Hepatotoxicity of erythromycin. , 1969, The Journal of infectious diseases.

[21]  M. Finland,et al.  Excretion of erythromycin and its enhanced activity in urine against gram-negative bacilli with alkalinization. , 1968, The Journal of laboratory and clinical medicine.

[22]  I. Gould,et al.  Phenoxymethyl penicillin versus co-amoxiclav in the treatment of acute streptococcal pharyngitis, and the role of beta-lactamase activity in saliva. , 1996, The Journal of antimicrobial chemotherapy.

[23]  D. Wortham,et al.  Comparison of the Effect of the Macrolide Antibiotics Erythromycin, Clarithromycin and Azithromycin on Terfenadine Steady-State Pharmacokinetics and Electrocardiographic Parameters , 1994 .

[24]  G. Foulds,et al.  The pharmacokinetics of azithromycin in human serum and tissues. , 1990, The Journal of antimicrobial chemotherapy.

[25]  J. Boyce,et al.  Induction of β-lactamase and methicillin resistance in unusual strains of methicillin-resistant Staphylococcus aureus , 1990 .

[26]  T. Ludden.  Pharmacokinetic Interactions of the Macrolide Antibiotics , 1985, Clinical pharmacokinetics.